Study guide
7.1 Major Depressive Disorder & Anxiety Disorders
Board Certified Ambulatory Care Pharmacist BCACP
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview & Patient Care Process
1.1 BCACP Exam Logistics, Blueprint & Pass Standards 1.2 The Pharmacists' Patient Care Process (PPCP) in Ambulatory Care 1.3 Communication, Health Literacy & Cultural Competence
2 Chapter 2: Cardiovascular I: Hypertension & Dyslipidemia
2.1 Hypertension Guidelines, Staging & Primary Regimens 2.2 Resistant Hypertension, Secondary Causes & Special Populations 2.3 Dyslipidemia: Statin Benefit Groups & Non-Statin Add-ons
3 Chapter 3: Cardiovascular II: Heart Failure, CAD & Anticoagulation
3.1 Heart Failure GDMT: HFrEF Four Pillars & HFpEF Management 3.2 Chronic Coronary Disease & Antiplatelet Strategies 3.3 Anticoagulation: Atrial Fibrillation, VTE & Peri-Procedural Care
4 Chapter 4: Endocrine & Metabolic Disorders
4.1 Type 2 Diabetes: Incretins, SGLT2i & Comorbidity Alignment 4.2 Advanced Diabetes: Insulin Regimens, CGM & Hypoglycemia 4.3 Thyroid & Adrenal Disorders in Ambulatory Care 4.4 Osteoporosis Screening, Prevention & Therapeutic Sequencing
5 Chapter 5: Respiratory Care & Pulmonology
5.1 Asthma Management: GINA/NAEPP Stepwise & SMART Therapy 5.2 COPD Management: GOLD Guidelines & Exacerbation Prevention 5.3 Inhalation Devices, Delivery Techniques & Patient Counseling
6 Chapter 6: Renal, Urological & Reproductive Health
6.1 Chronic Kidney Disease: KDIGO Guidelines & SGLT2i/nsMRA Care 6.2 Benign Prostatic Hyperplasia & Erectile Dysfunction 6.3 Women's Health: Contraception, Menopause & Teratogenicity
7 Chapter 7: Neuropsychiatry & Behavioral Health
7.1 Major Depressive Disorder & Anxiety Disorders 7.2 Bipolar Disorder & Schizophrenia Spectrum 7.3 Epilepsy & Movement Disorders (Parkinson's Disease) 7.4 Migraine Prevention, Acute Treatment & Headache Disorders
8 Chapter 8: Pain Management & Rheumatology
8.1 Chronic Pain, Opioid Stewardship & SUD Management 8.2 Osteoarthritis, Gout & Hyperuricemia 8.3 Rheumatoid Arthritis & Autoimmune Pharmacotherapy
9 Chapter 9: Infectious Diseases & Immunizations
9.1 Ambulatory Infections & Outpatient Antimicrobial Stewardship 9.2 HIV Pharmacotherapy, PrEP/PEP & Viral Hepatitis 9.3 Adult Immunization Schedules & ACIP Recommendations 9.4 Immunizations in Special & High-Risk Populations
10 Chapter 10: Geriatrics, Drug Interactions & Medication Safety
10.1 Geriatric Pharmacotherapy, Beers Criteria & Deprescribing 10.2 Drug Interactions, CYP450, P-gp & Transporters 10.3 Adverse Drug Events, High-Alert Medications & ISMP Safety
11 Chapter 11: Biostatistics, Study Design & Literature Evaluation
11.1 Biostatistical Principles, Hypothesis Testing & Power 11.2 Clinical Study Designs, Bias & Evidence Appraisal 11.3 Pharmacoeconomics: ICER, QALY & Value Metrics
12 Chapter 12: Practice Advancement, Quality & Healthcare Delivery
12.1 Collaborative Practice Agreements & Telehealth Practice 12.2 Quality Improvement, HEDIS & CMS Star Ratings 12.3 Care Transitions, Medication Reconciliation & SDOH 12.4 CMM Services, CPT Coding (99605-99607) & Practice Management 12.5 Clinical Ethics, Patient Advocacy & Conflicts of Interest
7.1 Major Depressive Disorder & Anxiety Disorders
Key Takeaways Explain This Topic AI
Major Depressive Disorder (MDD) diagnosis requires ≥5 of 9 DSM-5-TR symptoms (SIGECAPS) for ≥2 weeks with depressed mood or anhedonia mandatory; severity is quantified via PHQ-9 (scores 0–4 minimal, 5–9 mild, 10–14 moderate, 15–19 moderately severe, ≥20 severe).
SSRIs represent first-line therapy; citalopram requires strict dose caps (max 40 mg/day; max 20 mg/day if age >60, hepatic impairment, or CYP2C19 poor metabolizers) due to dose-dependent QTc prolongation, while sertraline is preferred in cardiovascular disease (SADHART trial).
Bupropion provides activating, weight-neutral therapy without sexual dysfunction but is contraindicated in seizure disorders and eating disorders (bulimia/anorexia); mirtazapine exhibits inverse dose-sedation pharmacology with marked sedation and appetite stimulation at 7.5–15 mg daily via potent H1 and 5-HT2C antagonism.
Monoamine oxidase inhibitors (MAOIs) require strict avoidance of dietary tyramine to prevent fatal hypertensive crises and demand mandatory washout periods (2 weeks for most antidepressants, 5 weeks for fluoxetine due to long-lived norfluoxetine).
Generalized Anxiety Disorder (GAD) first-line maintenance relies on SSRIs/SNRIs and scheduled buspirone; benzodiazepines must be restricted to short-term acute crisis bridging (1–2 weeks) with mandatory slow stepwise tapering to prevent life-threatening withdrawal seizures.
Last updated: September 2026
Major Depressive Disorder & Anxiety Disorders
Executive Summary: Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD) are ubiquitous, highly disabling psychiatric conditions managed extensively within ambulatory care practice. For the Board Certified Ambulatory Care Pharmacist (BCACP), mastering psychiatric pharmacotherapy requires precise application of validated diagnostic scoring instruments (PHQ-9, GAD-7), nuanced selection among first-line selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), tailored deployment of atypical antidepressants (bupropion, mirtazapine) based on patient-specific comorbidity phenotypes, execution of evidence-based switching and augmentation protocols for treatment-resistant depression, and rigorous stewardship of benzodiazepines to prevent dependence and withdrawal toxicity.
1. DSM-5-TR Diagnostic Criteria & PHQ-9 Staging for MDD
Under the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR), a formal diagnosis of Major Depressive Disorder requires the presence of at least 5 of the following 9 symptoms during the same 2-week period , representing a clear change from previous functioning. At least one of the symptoms must be either (1) Depressed mood or (2) Loss of interest or pleasure (Anhedonia) .
The SIGECAPS Diagnostic Mnemonic
- Letter Clinical Symptom Domain Diagnostic Description & Manifestations
- S Sleep disturbances Insomnia (initial, middle, or terminal) or Hypersomnia nearly every day
- I Interest (Anhedonia) Markedly diminished interest or pleasure in all or almost all daily activities
- G Guilt / Worthlessness Excessive, inappropriate guilt or feelings of worthlessness nearly every day
- E Energy loss Fatigue, lethargy, or loss of energy nearly every day
- C Concentration deficits Diminished ability to think, concentrate, or make everyday decisions
A Appetite / Weight changes Significant weight loss/gain (>5% body weight change in a month) or decrease/increase in appetite
P Psychomotor changes Observable psychomotor agitation (pacing, handwringing) or retardation (slow speech, body movements)
S Suicidal ideation Recurrent thoughts of death, recurrent suicidal ideation without a plan, or suicide attempt/plan
Exclusionary Rule: Symptoms must cause clinically significant distress or functional impairment and must not be attributable to the direct physiological effects of a substance (e.g., drug abuse, medication) or another medical condition (e.g., severe hypothyroidism, systemic lupus erythematosus). In addition, there must never have been a manic or hypomanic episode (which would redefine the diagnosis as Bipolar Disorder).
The Patient Health Questionnaire-9 (PHQ-9)
The PHQ-9 is a 9-item self-report questionnaire that scores each DSM-5-TR symptom from 0 (not at all) to 3 (nearly every day), yielding a total score between 0 and 27 points .
PHQ-9 Score Depression Severity Guideline-Directed Ambulatory Care Action Plan
0–4 None / Minimal No active clinical intervention required; reassess periodically.
5–9 Mild Psychoeducation, watchful waiting, exercise, sleep hygiene; consider psychotherapy if persistent.
10–14 Moderate Treatment plan indicated: Offer evidence-based psychotherapy (CBT) and/or first-line pharmacotherapy.
15–19 Moderately Severe Active pharmacotherapy (SSRI, SNRI, bupropion, or mirtazapine) combined with psychotherapy.
20–27 Severe Immediate pharmacotherapy initiation; consider psychiatric referral, crisis evaluation, or intensive management.
Suicide Risk Item (Item 9): Question 9 specifically assesses thoughts of self-harm or being better off dead. Any positive score (1, 2, or 3) mandates an immediate, comprehensive suicide risk assessment (e.g., Columbia-Suicide Severity Rating Scale [C-SSRS]), evaluating intent, plan, lethality, and access to lethal means.
Treatment Response & Remission Metrics:
Clinical Response: Defined as a ≥50% reduction in baseline PHQ-9 score.
Clinical Remission: Defined as achieving a PHQ-9 score < 5 points .
2. Selective Serotonin Reuptake Inhibitors (SSRIs): Comparative Clinical Pharmacology
SSRIs selectively block the presynaptic serotonin transporter (SERT / SLC6A4), increasing synaptic 5-HT concentrations in the somatodendritic and axon terminal regions of serotonergic neurons. They represent the universal first-line pharmacotherapy for MDD, GAD, Panic Disorder, OCD, and PTSD. +---------------------------------------------------------------------------------------------------------+
- | SSRI COMPARATIVE PHARMACOTHERAPY MATRIX |
- +------------------+-----------------------+------------------------+-------------------------------------+
- | Drug & Daily Dose| Primary Indications | Half-Life & Kinetics | Key Safety Nuances & Clinical Pearls|
- +------------------+-----------------------+------------------------+-------------------------------------+
- | **Sertraline** | MDD, GAD, OCD, PTSD, | Parent: ~26 hours | **Cardiovascular Gold Standard:** |
- | (Zoloft) | Panic, PMDD, SAD | Active Metabolite: | Drug of choice post-MI and in heart |
- | 50–200 mg/day | | N-desmethyl (~66 hours)| failure (SADHART trial). Frequent GI|
- | | | | upset (take with meals/breakfast). |
- +------------------+-----------------------+------------------------+-------------------------------------+
- | **Escitalopram** | MDD, GAD | ~27–32 hours | **Pure S-Enantiomer:** Highly |
- | (Lexapro) | | Linear kinetics | selective SERT inhibitor; minimal |
- | 10–20 mg/day | | | CYP interactions; very well |
- | | | | tolerated. Max 10 mg/day in elderly.|
- +------------------+-----------------------+------------------------+-------------------------------------+
- | **Citalopram** | MDD | ~35 hours | **Strict FDA QTc Boxed Warning:** |
- | (Celexa) | | Racemic (R/S) mixture | Max 40 mg/day in adults; **Max 20 |
- | 20–40 mg/day | | | mg/day** if age >60, hepatic impair,|
- | | | | CYP2C19 poor metabolizers, or with |
- | | | | CYP2C19 inhibitors (cimetidine). |
- +------------------+-----------------------+------------------------+-------------------------------------+
- | **Fluoxetine** | MDD, OCD, Panic, | Fluoxetine: 1–3 days | **Activating & Self-Tapering:** |
- | (Prozac) | Bulimia, PMDD, Bipolar| Norfluoxetine: 7–15 | Longest half-life; lowest risk of |
- | 20–80 mg/day | depression (with OFC) | days (CYP2D6 inhibitor)| discontinuation syndrome. Requires |
- | | | | **5-week washout** before MAOIs. |
- +------------------+-----------------------+------------------------+-------------------------------------+
- | **Paroxetine** | MDD, GAD, OCD, PTSD, | ~21 hours | **Anticholinergic & Teratogenic:** |
- | (Paxil, Pexeva) | Panic, SAD, VMS | Potent CYP2D6 inhibitor| Most sedating, anticholinergic, and |
- | 20–50 mg/day | (Brisdelle 7.5 mg) | Non-linear kinetics | weight-gain prone. Highest risk of |
- | | | | withdrawal; avoid in pregnancy (VSD)|
- +------------------+-----------------------+------------------------+-------------------------------------+
- Critical Class Adverse Effects & Safety Management
Gastrointestinal Effects: Nausea, vomiting, diarrhea (mediated by stimulation of peripheral 5-HT3 and 5-HT4 receptors). Typically resolves within 1–2 weeks; counsel patients to take doses with food.
Sexual Dysfunction: Decreased libido, erectile dysfunction, delayed ejaculation, and anorgasmia (mediated by 5-HT2A stimulation). Persists throughout therapy; manage by dose reduction, switching to bupropion or mirtazapine, or augmenting with sildenafil/tadalafil or bupropion.
Hyponatremia / SIADH: Syndrome of Inappropriate Antidiuretic Hormone secretion occurs disproportionately in elderly patients, those on thiazide diuretics, or with low baseline volume. Monitor serum sodium within 2–4 weeks of initiation.
Bleeding Risk: Platelets depend on SERT to take up serotonin necessary for platelet aggregation. SERT blockade increases the risk of upper GI bleeding, especially when co-prescribed with NSAIDs, aspirin, or oral anticoagulants (consider gastroprotection with a PPI).
Bone Mineral Density Loss: Long-term SSRI use is associated with increased osteoporotic fracture risk.
Antidepressant Discontinuation Syndrome (FINISH Mnemonic): F lu-like symptoms, I nsomnia, N ausea, I mbalance (dizziness, vertigo), S ensory disturbances ("brain zaps", electric shock sensations), and H yperarousal (anxiety, agitation). Most pronounced with short half-life agents lacking active metabolites (paroxetine, venlafaxine); least common with fluoxetine. Always taper gradually over 2–4+ weeks.
- 3. SNRIs, Bupropion, Mirtazapine, TCAs & MAOIs
- Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
SNRIs inhibit both SERT and the norepinephrine transporter (NET / SLC6A2), elevating central 5-HT and NE. They are especially beneficial in patients with comorbid chronic pain, diabetic neuropathy, or fibromyalgia.
Venlafaxine (Effexor XR: 75–225 mg/day):
Dose-Dependent Receptor Affinity: At low doses (<150 mg/day), venlafaxine acts almost exclusively as an SSRI. At doses ≥150 mg/day, NET inhibition becomes clinically significant.
Hemodynamic Impact: Dose-dependent increases in blood pressure (average 2–5 mmHg diastolic elevation) and heart rate. Baseline BP must be controlled prior to initiation, and blood pressure monitored regularly.
Duloxetine (Cymbalta: 30–60 mg once daily, max 120 mg/day):
Balanced Dual Reuptake Inhibition: Potent SERT and NET inhibition across its full therapeutic dosing range.
Multispecialty FDA Indications: MDD, GAD, Diabetic Peripheral Neuropathic Pain (DPNP), Fibromyalgia, and Chronic Musculoskeletal Pain (low back pain, osteoarthritis).
Hepatic & Renal Restrictions: Strictly avoid in patients with substantial alcohol use, evidence of chronic liver disease, or severe renal impairment ( CrCl < 30 mL/min ).
Desvenlafaxine (Pristiq: 50 mg once daily, max 100 mg/day): Active major metabolite of venlafaxine; eliminates reliance on CYP2D6 polymorphisms, providing consistent pharmacokinetics.
Norepinephrine-Dopamine Reuptake Inhibitor (NDRI): Bupropion
Bupropion inhibits the reuptake of norepinephrine (NET) and dopamine (DAT) without direct serotonergic activity.
Clinical Advantages: Highly activating (energizing), promotes cognitive focus, weight neutral or promotes modest weight loss, and carries zero incidence of sexual dysfunction (frequently used as an antidote to SSRI-induced sexual dysfunction). Also FDA approved for smoking cessation under the trade name Zyban.
Strict Boxed Warning & Contraindications — Seizure Risk:
Bupropion lowers the seizure threshold in a dose-dependent manner (incidence ~0.1% at ≤300 mg XL, rising to 0.4% at 450 mg XL).
Absolute Contraindications: (1) Active seizure disorder or history of seizures, (2) Current or prior diagnosis of Bulimia Nervosa or Anorexia Nervosa (high incidence of severe grand mal seizures due to electrolyte instability), (3) Abrupt discontinuation of alcohol, benzodiazepines, barbiturates, or antiepileptic drugs, (4) Co-administration with MAOIs (requires 14-day washout).
Maximum single dose for IR is 150 mg; maximum daily dose for XL is 450 mg/day.
Noradrenergic & Specific Serotonergic Antidepressant (NaSSA): Mirtazapine
Mirtazapine (Remeron: 15–45 mg once daily at bedtime) is an antagonist at central presynaptic alpha-2 adrenergic auto- and hetero-receptors , increasing noradrenergic and serotonergic transmission, while simultaneously blocking postsynaptic 5-HT2A, 5-HT2C, 5-HT3 , and H1 histaminergic receptors .
Inverse Dosing / Receptor Affinity Paradox:
Low Doses (7.5–15 mg/day): Potent H1-histamine receptor and 5-HT2C receptor antagonism dominate, producing intense sedation, increased appetite, and significant weight gain (highly advantageous for frail, underweight elderly patients with severe insomnia and cachexia).
Higher Doses (30–45 mg/day): Increased central noradrenergic transmission offsets H1 sedation, resulting in a more activating antidepressant profile with less somnolence.
Safety Profile: Virtually zero sexual dysfunction (due to 5-HT2A blockade) and antiemetic properties (due to 5-HT3 blockade).
Tricyclic Antidepressants (TCAs) & Monoamine Oxidase Inhibitors (MAOIs)
Drug Class Representative Agents Key Mechanisms Adverse Effect Profile & Toxicity Warning
Tertiary Amine TCAs Amitriptyline (Elavil); Imipramine (Tofranil); Doxepin (Sinequan) Inhibit SERT > NET; strong alpha-1, H1, and muscarinic (M1) receptor blockade High Anticholinergic & Sedating Burden: Dry mouth, urinary retention, severe constipation, blurred vision, orthostatic hypotension, weight gain. Beers Criteria avoid in older adults.
Secondary Amine TCAs Nortriptyline (Pamelor); Desipramine (Norpramin) Inhibit NET > SERT; active demethylated metabolites of tertiary amines Better Tolerated: Significantly less anticholinergic, less sedating, and lower orthostasis than tertiary amines. Nortriptyline has a defined therapeutic window (50–150 ng/mL).
TCA Overdose Toxicity All TCAs Cardiac Fast Sodium Channel Blockade (phase 0 depolarization) Lethal in Small Overdoses (1–2 g): Widened QRS complex (>100 ms), fatal ventricular arrhythmias (torsades, V-tach, V-fib), refractory hypotension, seizures. Antidote: IV Sodium Bicarbonate to overcome sodium channel blockade and alkalinize serum pH to 7.45–7.55.
MAOIs Phenelzine (Nardil); Tranylcypromine (Parnate); Isocarboxazid (Marplan); Selegiline patch (Emsam) Irreversible non-selective inhibition of MAO-A (breaks down 5-HT, NE) and MAO-B (breaks down DA, tyramine) Hypertensive Crisis ("Cheese Effect"): Dietary tyramine is normally metabolized by GI MAO-A. MAO inhibition allows tyramine to enter systemic circulation, displacing massive norepinephrine stores. Requires strict low-tyramine diet (avoid aged cheeses, cured meats, draft beers, fava beans, soy sauce, Marmite).
Absolute Practice Rule — MAOI Washout Periods: Co-administration of MAOIs with serotonergic agents (SSRIs, SNRIs, TCAs, meperidine, tramadol, dextromethorphan, linezolid) precipitates fatal Serotonin Syndrome . A mandatory 14-day (2-week) washout is required when switching between an MAOI and other antidepressants. When switching from Fluoxetine to an MAOI , a 5-week (35-day) washout is mandatory due to the prolonged elimination half-life of fluoxetine and its active metabolite norfluoxetine.
Loading diagram... Clinical Decision Algorithm for MDD Pharmacotherapy & Treatment Resistance
4. Generalized Anxiety Disorder (GAD) & Benzodiazepine Stewardship
Generalized Anxiety Disorder (GAD) is characterized by excessive, uncontrollable worry and anxiety occurring more days than not for at least 6 months , accompanied by somatic symptoms (muscle tension, restlessness, fatigue, impaired concentration, irritability, sleep disturbance). Severity is tracked using the GAD-7 scale (0–4 minimal, 5–9 mild, 10–14 moderate, 15–21 severe).
First-Line Maintenance Pharmacotherapy for GAD
SSRIs (Escitalopram, Sertraline, Paroxetine) & SNRIs (Duloxetine, Venlafaxine XR): Established first-line therapies providing long-term symptom control and preventing relapse without abuse liability.
Clinical Initiation Rule ("Start Low, Go Slow"): Patients with anxiety are hyper-sensitive to initial activating/jitteriness adverse effects. Initiate at half the standard starting dose for depression (e.g., escitalopram 5 mg daily, sertraline 25 mg daily, duloxetine 30 mg daily) for 1–2 weeks before titrating to full therapeutic target doses.
Buspirone (BuSpar: 7.5 mg BID, titrate to 15–30 mg BID; max 60 mg/day):
Mechanism: High-affinity 5-HT1A presynaptic and postsynaptic partial agonist , providing anxiolysis without sedation, muscle relaxation, or anticonvulsant activity.
Zero Abuse Liability: Not a controlled substance; no physical dependence, tolerance, or withdrawal syndrome.
Pharmacokinetic Pearls: Must be taken consistently either with food or without food (food increases bioavailability 2-fold). Delayed onset of action (2 to 4 weeks) ; buspirone is completely ineffective as an acute as-needed (PRN) anxiolytic.
Benzodiazepines: Acute Crisis Bridging & Deprescribing Protocols
Benzodiazepines (lorazepam, clonazepam, alprazolam, diazepam) act as positive allosteric modulators of the GABAA receptor , increasing chloride channel opening frequency to produce immediate central nervous system depression. +---------------------------------------------------------------------------------------+
- | BENZODIAZEPINE AMBULATORY STEWARDSHIP RULES |
- +------------------------------------+--------------------------------------------------+
- | Clinical Domain | Mandatory Ambulatory Practice Rule |
- +------------------------------------+--------------------------------------------------+
- | Role in GAD / Panic Therapy | Strictly restricted to **short-term acute crisis |
- | | management (1 to 2 weeks)** or as a brief bridge |
- | | while initiating an SSRI/SNRI. |
- +------------------------------------+--------------------------------------------------+
- | Geriatric Safety (Beers Criteria) | **Avoid in older adults (Age >= 65)** due to high|
- | | risk of cognitive impairment, delirium, motor |
- | | incoordination, falls, and hip fractures. |
- +------------------------------------+--------------------------------------------------+
- | FDA Boxed Warning with Opioids | Co-prescribing opioids and benzodiazepines |
- | | produces profound sedation, respiratory |
- | | depression, coma, and fatal overdose. |
- +------------------------------------+--------------------------------------------------+
- | Withdrawal Seizure Risk | Abrupt cessation of chronic benzodiazepines |
- | | triggers severe autonomic hyperactivity, rebound |
- | | anxiety, delirium tremens, and status epilepticus|
- +------------------------------------+--------------------------------------------------+
- | Guideline Deprescribing Taper | **Slow Stepwise Taper:** Reduce total daily dose |
- | | by **10% to 25% every 1 to 2 weeks** over several|
- | | months. Convert short-acting agents (alprazolam) |
- | | to long-acting agents (clonazepam, diazepam) |
- | | if withdrawal symptoms emerge during tapering. |
- +------------------------------------+--------------------------------------------------+